Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sernova Biotherapeutics Inc
(TSV:
SVA
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Jun 1, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sernova Biotherapeutics Inc
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
May 06, 2022
From
Sinovac Biotech Ltd.
Via
Business Wire
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
April 29, 2022
From
Sinovac Biotech Ltd.
Via
Business Wire
Sinovac Amends Shareholder Rights Plan
February 22, 2022
From
Sinovac Biotech Ltd.
Via
Business Wire
SINOVAC Reports Unaudited First Half of 2021 Financial Results
December 30, 2021
From
Sinovac Biotech Ltd.
Via
Business Wire
Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
December 09, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
SINOVAC Beijing Settled Litigation of Its Business License and Seals
December 03, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
November 09, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
September 09, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
September 08, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
August 10, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
July 19, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
July 12, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
June 30, 2021
From
Sinovac Biotech Ltd.
Via
Business Wire
World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use
June 02, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
April 22, 2021
From
Sinovac Biotech Ltd.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today